| UniProt | <a href="https://www.
ApoE is a 299-amino acid apolipoprotein:
- N-terminal (1-191): Four-helix bundle structure, LDL receptor-binding region
- C-terminal (192-299): Lipid-binding domain
- Receptor-binding region: Sites 130-150 (LDLR binding)
- Heparan sulfate binding region: Lys/Arg-rich clusters
Three common isoforms (APOE ε2, ε3, ε4) differ at positions 112 and 158.
ApoE is the primary apolipoprotein in the brain:
- Lipid transport: Mediates cholesterol and phospholipid transport
- Lipoprotein metabolism: Component of HDL-like particles
- Neuronal repair: Required for membrane maintenance and synapse formation
- Aβ interaction: Binds to amyloid-beta, influences its metabolism
- Neuroprotection: Antioxidant and anti-inflammatory properties
ApoE is produced primarily by astrocytes in the brain.
- Risk alleles:
- APOE ε4: Major genetic risk factor
- APOE ε2: Potentially protective
- APOE ε3: Most common
- Mechanisms:
- Altered Aβ aggregation and clearance
- Enhanced neuroinflammation
- Impaired synaptic plasticity
- Accelerated tau pathology
- APOE ε4 associated with hypercholesterolemia
- Increased atherosclerosis risk
- Gene therapy: APOE ε2 or ε3 delivery to ε4 carriers
- Small molecule modulators: APOE isoform-specific approaches
- Aβ vaccination: Considering APOE genotype
-
Corder EH, et al. (1993). "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease." Science. PMID:8346443
-
Strittmatter WJ, et al. (1993). "Apolipoprotein E: high-avidity binding to beta-amyloid." Proc Natl Acad Sci. PMID:8341694
-
Huang Y, et al. (2021). "APOE functions and therapeutic targets in Alzheimer disease." Nat Rev Neurol. PMID:33442041
The study of Apoe Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
- 1 Strittmatter WJ, et al. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. PMID:8341693.
- 2 Roses AD. (1994). Apolipoprotein E affects the rate of Alzheimer disease expression: a biochemical genetic and preventive medicine. Am J Hum Genet. PMID:8306885.
- 3 Mahley RW. (2016). Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med. PMID:26928900.
- 4 Liu CC, et al. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. PMID:23338189.
- 5 Huang Y, et al. (2004). Apolipoprotein E and Alzheimer disease: the role of mutations in the coding sequence. Nat Rev Neurosci. PMID:14735134.
-
- See: APOE Gene - Gene encoding this protein
- See: Alzheimer's disease - Disease context
- See: amyloid-beta - Interaction with Aβ
- See: astrocytes - Cellular expression
- See: Cholesterol Metabolism - Metabolic pathway
APOE alleles confer dramatically different AD risk:
| Allele |
Frequency |
AD Risk |
Age of Onset |
| APOE ε2 |
5-10% |
Protective |
Later |
| APOE ε3 |
75-80% |
Baseline |
Typical |
| APOE ε4 |
10-15% |
3-4x increased |
Earlier |
- Homozygous ε4/ε4: 10-12x increased risk
- Heterozygous ε4/ε3: 2-3x increased risk
- ε2/ε2: May be protective against AD
APOE4 contributes to AD through multiple mechanisms:
-
Aβ metabolism
- Reduced Aβ clearance
- Enhanced aggregation
- Altered trafficking
-
Tau pathology
- Increased tau phosphorylation
- Enhanced neurofibrillary tangle formation
-
Synaptic dysfunction
- Impaired synaptic plasticity
- Reduced neurite outgrowth
-
Neuroinflammation
- Enhanced microglial activation
- Pro-inflammatory phenotype
APOE is essential for lipid homeostasis:
- Cholesterol transport: Redistributes lipids between cells
- HDL formation: Nucleates HDL particle formation
- Aβ binding: Lipidated APOE binds Aβ
- Risk prediction: APOE genotyping informs risk
- Not diagnostic: Risk factor, not deterministic
- Counselling: Important for interpretation
- CSF Aβ42: Lower in APOE4 carriers
- PET amyloid: Earlier positivity in ε4 carriers
- Tau levels: Higher in APOE4 carriers
APOE4 as a therapeutic target:
- APOE mimetics: Peptide analogs
- Gene therapy: Increase APOE2 expression
- Small molecules: Modulators of APOE expression
- Anti-Aβ antibodies: Enhanced efficacy in APOE4
- Vaccination: Different responses by genotype
- Aggregation inhibitors: Genotype-specific
¶ Domain Organization
- N-terminal (1-191): Receptor binding domain
- Linker region (192-299): Flexible hinge
- C-terminal (300-299): Lipid binding domain
- APOE2: Cys130, Arg176, Arg178
- APOE3: Cys130, Arg176, Cys178
- APOE4: Arg130, Arg176, Arg178
These changes affect:
- Receptor binding affinity
- Lipid binding properties
- Structural stability
- Atherosclerosis: APOE4 increases risk
- Dyslipidemia: Alters cholesterol metabolism
- Stroke: Independent risk factor
- Parkinson's disease: Variable effects
- FTLD: Risk factor in some cohorts
- ALS: Possible modifier
- APOE fragments: Diagnostic potential
- Lipid profiles: Correlate with risk
- Response predictors: Therapy optimization
- APOE-directed: Gene therapy, mimetics
- Personalized medicine: Genotype-stratified
- Prevention trials: Targeting ε4 carriers
|
|---|